“Challenges of a Large Pragmatic Trial: the ALLHAT Experience”

Thursday, June 28, 2018
4:30 p.m. in the Doll & Hill Room
Taylor Avenue Building

Major clinical trial and statistical challenges will be presented from the Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial (ALLHAT) trial. This data set was a large (n=42,418), pragmatic, randomized, double-blind, active-controlled hypertension treatment trial designed to compare a calcium channel blocker (amlodipine), an ACE-inhibitor (lisinopril), or an α-blocker (doxazosin), each compared to a diuretic (chlorthalidone), in reducing risk of coronary heart disease. ALLHAT enrolled a broadly representative patient population from 623 clinics. It was conducted in typical health care settings, used broad inclusion criteria, and was minimally intrusive on routine clinical practice.

Join us for a reception in the break area after the presentation.

For more information:
Katy Henke (314) 454-7650
k.henke@wustl.edu

www.publichealthsciences.wustl.edu